CLNN - Clene Inc.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies.
As of Aug 14, 2026: spot at $4.21, ATM IV 22.7%, max pain $7.50, net GEX $21.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $52.0M
- Beta
- 0.97
- 52-Week Range
- 3.5-13.5
- CEO
- Robert Etherington
- Employees
- 78
- IPO Date
- Oct 18, 2018
- Exchange
- NASDAQ
What CLNN Looks Like to Options Traders Today
IV rank of 1.5% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($21) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes.
What This Page Covers
The CLNN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked CLNN overview questions
- What is CLNN?
- CLNN is the ticker symbol for Clene Inc., a listed security. Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). Listed on NASDAQ. CLNN is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the CLNN options snapshot look like today?
- As of Aug 14, 2026, the CLNN options snapshot shows spot at $4.21, ATM IV 22.7%, IV rank 1.5%, max pain $7.50, net GEX $21, expected move 6.51%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are CLNN's key statistics?
- Clene Inc. (CLNN) carries a market capitalization of $52.0M, beta of 0.97 relative to the broader market, 52-week range of 3.5-13.5. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does CLNN belong to?
- Clene Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare CLNN's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the CLNN data on this page?
- The options snapshot above is dated Aug 14, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).